Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

In the assessment of 12-month price targets, analysts unveil insights for Bristol-Myers Squibb, presenting an average target ...

Bristol Myers Squibb is the century-old pharmaceutical giant that markets the oral blood thinner Eliquis in partnership with ...

Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) on September 6 and set a price ...

Bristol Myers Squibb (NYSE: BMY) has struggled to manage the loss of exclusivity now that some of its top-selling drugs are facing competition from generics. Disappointing results from the ...

The first undervalued wide-moat stock on our list is Bristol Myers Squibb. The drugmaker’s portfolio covers ... Customers ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Bristol Myers Squibb is ending its collaboration with Immatics on IMA401, effective December 12, as part of portfolio ...

Delayed diagnosis and treatment of CCCA result in insufficiently aggressive therapy and risks an avoidable consequence, ...